Literature DB >> 577211

Triiodothyronine, thyroxine, and iodine in purified thyroglobulin from patients with Graves' disease.

M Izumi, P R Larsen.   

Abstract

Previous studies have suggested that there is an overproduction of triiodothyronine (T(3)) relative to thyroxine (T(4)) in patients with thyrotoxicosis associated with Graves' disease. To evaluate whether or not an increased ratio of T(3) to T(4) in thyroidal secretion could be contributing to this relative T(3) hyperproduction, T(3), T(4), and iodine were measured in thyroglobulin (Tg) from controls and patients with Graves' disease who had been treated either with propranolol only or with antithyroid drugs plus iodide before surgery. To avoid possible artifacts associated with pulse labeling and chromatography, T(3) and T(4) were determined by radioimmunoassay of Pronase hydrolysates of purified Tg. Results of analyses of Tg from six control patients and seven with Graves' disease, not receiving thiourea drugs or iodide, showed that the iodine content of Graves' disease Tg was not different from normal. Both contained 3.4 residues of T(4)/molecule Tg, but there was 0.39+/-0.08 (mean+/-SD) residue of T(3)/molecule Tg in Graves' Tg as opposed to 0.23+/-0.07 residue T(3) molecule Tg in controls matched for iodine content (P < 0.01). This difference resulted in a significantly lower T(4)/T(3) molar ratio (9+/-2) in Graves' Tg as opposed to control (15+/-2, P < 0.001). In Tg from patients with treated Graves' disease, iodine, T(3), and T(4) were reduced, but the reduction in the latter was more substantial, resulting in a T(4)/T(3) molar ratio of 3.4+/-1. Fractionation of Tg from all groups by RbCl density gradient ultracentrifugation indicated that at physiological levels of Tg iodination, the molar ratio of T(3)/Tg was consistently higher in Graves' disease. The specific mechanism for this difference is not known, but it is not due to iodine deficiency. If T(3) and T(4) are secreted in this altered ratio in patients with Graves' disease, the magnitude of the difference could explain the relative T(3) hyperproduction which is characteristic of this state.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 577211      PMCID: PMC372323          DOI: 10.1172/JCI108734

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  A STUDY OF THE MECHANISMS INVOLVED IN THE PRODUCTION OF IODINE-DEFICIENCY GOITER.

Authors:  H STUDER; M A GREER
Journal:  Acta Endocrinol (Copenh)       Date:  1965-08

2.  Biochemical observations in functioning human thyroid adenomas.

Authors:  P R Larsen; K Yamashita; A Dekker; J B Field
Journal:  J Clin Endocrinol Metab       Date:  1973-05       Impact factor: 5.958

3.  Effect of propranolol on various aspects of thyroid function in the rat.

Authors:  F Azizi; A G Vagenakis; J E Bush; L E Braverman
Journal:  Metabolism       Date:  1974-06       Impact factor: 8.694

4.  The measurement of serum triiodothyronine by double column chromatography.

Authors:  J H Dussault; R Lam; D A Fisher
Journal:  J Lab Clin Med       Date:  1971-06

5.  Digestion of 131I-labeled thyroid tissue with maximum recovery of 131I-iodothyronines.

Authors:  K Inoue; A Taurog
Journal:  Endocrinology       Date:  1967-08       Impact factor: 4.736

6.  T3 thyrotoxicosis. Thyrotoxicosis due to elevated serum triiodothyronine levels.

Authors:  K Sterling; S Refetoff; H A Selenkow
Journal:  JAMA       Date:  1970-07-27       Impact factor: 56.272

7.  Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.

Authors:  P R Larsen
Journal:  J Clin Endocrinol Metab       Date:  1975-12       Impact factor: 5.958

8.  Acute and chronic responses to iodine deficiency in rats.

Authors:  G Riesco; A Taurog; R Larsen; L Krulich
Journal:  Endocrinology       Date:  1977-02       Impact factor: 4.736

9.  Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents.

Authors:  J Abuid; P R Larsen
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

10.  TSH stimulation of iodothyronine formation in prelabeled thyroglobulin of hypophysectomized rats.

Authors:  M A Greer; C F Allen; J Torresani; M Roques; S Lissitzky
Journal:  Endocrinology       Date:  1974-05       Impact factor: 4.736

View more
  15 in total

1.  Two cases of Graves' disease with antithyroid hormone antibodies: implication on the role of thyroglobulin as an antigen.

Authors:  S Sakata; K Nagai; O Tarutani; Y Kohno; K Saito; T Komaki; H Takuno; M Matsuda; T Ogawa; N Tokimitsu
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

Review 2.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

3.  Type 2 iodothyronine deiodinase is highly expressed in human thyroid.

Authors:  D Salvatore; H Tu; J W Harney; P R Larsen
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

4.  Effect of chronic ingestion of sodium acetate on thyroid function.

Authors:  M Goldman
Journal:  Experientia       Date:  1981-12-15

Review 5.  Physiological role and regulation of iodothyronine deiodinases: a 2011 update.

Authors:  A Marsili; A M Zavacki; J W Harney; P R Larsen
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

6.  De novo triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone.

Authors:  Cintia E Citterio; Balaji Veluswamy; Sarah J Morgan; Valerie A Galton; J Paul Banga; Stephen Atkins; Yoshiaki Morishita; Susanne Neumann; Rauf Latif; Marvin C Gershengorn; Terry J Smith; Peter Arvan
Journal:  J Biol Chem       Date:  2017-07-25       Impact factor: 5.157

7.  Development of thyroid function between VI-IX month of fetal life in humans.

Authors:  A Costa; V De Filippis; M Panizzo; G Giraudi; E Bertino; R Arisio; M Mostert; G Trapani; C Fabris
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

8.  New insights into thyroid hormone replacement therapy.

Authors:  Brenda M Acosta; Antonio C Bianco
Journal:  F1000 Med Rep       Date:  2010-05-11

Review 9.  Thyroglobulin From Molecular and Cellular Biology to Clinical Endocrinology.

Authors:  Bruno Di Jeso; Peter Arvan
Journal:  Endocr Rev       Date:  2015-11-23       Impact factor: 19.871

10.  The role of the iodothyronine deiodinases in the physiology and pathophysiology of thyroid hormone action.

Authors:  P Reed Larsen; Ann Marie Zavacki
Journal:  Eur Thyroid J       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.